Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pathological and molecular characterization of a four-component combined small cell lung carcinoma: a case report.

Translational lung cancer research·2026

Same author

Feasibility study of photoimmunotherapy combination with ASP-1929 for vulvar, vaginal, and cervical cancer.

Journal of gynecologic oncology·2026

Same author

Hokkaido phase II study of photo-immunotherapy combination with ASP-1929 for recurrent or persistent EGFR-positive vulvar, vaginal, and cervical cancers not amenable to further radiotherapy (HICARi study).

Journal of gynecologic oncology·2026

Same author

Extraskeletal Myxoid Chondrosarcoma Mimicking Myoepithelial Tumor.

Case reports in pathology·2026

Same author

A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026

Same author

Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).

Future oncology (London, England)·2026

Search research articles

Related Experiment Video

Updated: May 6, 2026

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic

Takeaki Nakamura¹, Kanako C Hatanaka², Yasuyuki Kawamoto³

¹Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan.

Journal of Cancer Research and Clinical Oncology

|May 9, 2025

Summary

Schlafen family member 11 (SLFN11) expression was studied in pancreatic ductal adenocarcinoma (PDAC) to predict chemotherapy response. However, SLFN11 levels did not correlate with treatment efficacy or patient survival outcomes in this cohort.

Keywords:

Biomarker Chemotherapy Immunohistochemistry Pancreatic ductal adenocarcinoma Prognosis SLFN11

More Related Videos

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Related Experiment Videos

Last Updated: May 6, 2026

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Area of Science:

Oncology
Molecular Biology
Cancer Biomarkers

Background:

Pancreatic ductal adenocarcinoma (PDAC) presents a significant clinical challenge with poor prognoses, even with aggressive chemotherapy.
Schlafen family member 11 (SLFN11) is implicated in DNA damage response and may influence sensitivity to chemotherapy agents.

Purpose of the Study:

To investigate the expression of SLFN11 in PDAC tissues.
To evaluate SLFN11 as a potential biomarker for predicting chemotherapy efficacy and survival in PDAC patients.

Main Methods:

Retrospective analysis of 158 PDAC patients receiving palliative chemotherapy.
Immunohistochemical assessment of SLFN11 expression using H-score on biopsy specimens.
Correlation analysis of SLFN11 expression with progression-free and overall survival using Kaplan-Meier and Cox regression.

Main Results:

SLFN11 expression was detected in 54.4% of PDAC samples.
Higher SLFN11 expression (median H-score) was noted in metastatic PDAC compared to locally advanced and borderline resectable cases.
No significant association was found between SLFN11 expression levels and chemotherapy efficacy or clinical outcomes (PFS, OS).

Conclusions:

SLFN11 did not demonstrate utility as a predictive biomarker for chemotherapy efficacy in this cohort of PDAC patients.
Further research with larger patient groups and refined staging is warranted to fully elucidate SLFN11's role in PDAC treatment.